Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.

MLA

Lanzafame, Massimiliano, et al. “Comment on: Unboosted Fosamprenavir Is Associated with Low Drug Exposure in HIV-Infected Patients with Mild-Moderate Liver Impairment Resulting from HCV-Related Cirrhosis.” The Journal of Antimicrobial Chemotherapy, vol. 64, no. 1, July 2009, pp. 215–16. EBSCOhost, https://doi.org/10.1093/jac/dkp105.

APA

Lanzafame, M., Lattuada, E., & Corsini, F. (2009). Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. The Journal of Antimicrobial Chemotherapy, 64(1), 215–216. https://doi.org/10.1093/jac/dkp105

Chicago

Lanzafame, Massimiliano, Emanuela Lattuada, and Fabiana Corsini. 2009. “Comment on: Unboosted Fosamprenavir Is Associated with Low Drug Exposure in HIV-Infected Patients with Mild-Moderate Liver Impairment Resulting from HCV-Related Cirrhosis.” The Journal of Antimicrobial Chemotherapy 64 (1): 215–16. doi:10.1093/jac/dkp105.